News

FDA advisory panel nixes approval of drug-device for liver metastases


 

AT AN FDA ADVISORY PANEL MEETING

About 2,000 cases of ocular melanoma are diagnosed annually in the United States and about 50% metastasize, most often to the liver, according to Delcath. In Europe and Australia, the company markets the device for a broad range of liver metastases, not just those caused by ocular melanoma, according to the company.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Cancer incidence and mortality hit blacks hardest
MDedge Dermatology
Aspirin may protect older women from melanoma
MDedge Dermatology
Ipilimumab plus surgery boosted advanced melanoma survival
MDedge Dermatology
One in four melanoma patients shun sunscreen
MDedge Dermatology
Are dermatologists falling behind the technology curve?
MDedge Dermatology
Melanoma increases in adolescents
MDedge Dermatology
Be mindful of psoriasis/cutaneous T-cell lymphoma link
MDedge Dermatology
Therapeutic combos make inroads in advanced melanoma
MDedge Dermatology
Preimmunosuppresive hepatitis B screening often goes by the wayside
MDedge Dermatology
FDA: Tanning lamps should warn against skin cancer
MDedge Dermatology

Related Articles